Turn Therapeutics Inc (TTRX)

Q: What's priced into Turn Therapeutics Inc (TTRX) stock?

The evidence does not provide a peer valuation comparison or a clear account of what expectations are reflected in the valuation. TTRX is loss-making, so the available evidence does not support a firm view on whether it is cheap, fair, or expensive.

Q: What does the Turn Therapeutics Inc (TTRX) outlook hinge on?

Over the next one to three years, the thesis depends on trial progress and whether the planned expansion into other indications advances. The wider Healthcare sector is a near-term tailwind, but weakening jobs data or poorer results and guidance from sector bellwethers could weaken that support.

NASDAQHealth CareBiotechnologySnapshot 2026-10-23

$10.28+0.98%

Close 2026-10-23 · 1-day change

Investment OutlookAs of Oct 24, 2026

What could strengthen or challenge Turn Therapeutics Inc’s outlook?

The long-term thesis, the evidence coming in, and the environment around it. Thesis dated Jul 8, 2026.

Higher potential upsideImproving expectations

Next-FY EPS estimate change · 30 days

Comparable estimates unavailable

+10% or more+5%0%−5%−10% or less

A matching fiscal period and sufficient coverage are required.

Higher risk of downsideWeakening expectations

One observable signal. This measures changing earnings expectations, not the probability of a gain or loss.

How this is measured

The calculation requires same-period, same-provider snapshots, positive EPS, at least five analysts and a baseline within three days of the requested lookback.

Measure / period	Management expectations	Analyst expectations
Quarter ending 2026-12-30
Revenue	—	250,000
EPS	—	-0.12
Annual ending 2026-12-31
Revenue	—	300,000
EPS	—	-0.44
Annual ending 2027-12-31
Revenue	—	3.37M
EPS	—	-0.42

Management figures unavailable.

What the Thesis Depends On

4 published thesis conditions, with dated milestones shown separately.

Key Factor	Why It Matters	Current Status	Break Condition	Latest Evidence
Expand board with independent directors for better governance	New board members improve leadership.	Intact	No new independent directors added within next 4 quarters	Qualitative condition This condition has no defined numerical measure. Context reviewed through Oct 23, 2026Last status assessment Oct 24, 2026Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement.
Manage loans and financial obligations to support growth	A supporting condition in Turn Therapeutics Inc's published investment case. The stated target is Maintain loan agreements and financial obligations without default.	Intact	Default or failure to manage financial obligations within next 4 quarters	No default reported Recent private placements and warrant issuances show active capital raising; no default or financial obligation failures reported. Context reviewed through Oct 23, 2026Last status assessment Oct 24, 2026Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement.
Operating income loss stays near or below -$1.25 million	They manage losses near $1.2 million operating loss in 2026-Q1.	Under Pressure	Operating income loss worsens beyond -$1,250,000 next quarter	Operating income: $-1.628M FY2026-Q2; GAAP. Published target: Operating income loss <= -$1,250,000. The stored target says 2026-Q1; this source reports FY2026-Q2. Fiscal/calendar alignment needs review. Source published Aug 12, 2026-1,628,060 USD · source valueSource reportLast status assessment Oct 24, 2026 Measurement source consolidated · GAAP FY2026-Q2 · Period ending Jun 30, 2026 Source: company_financial_results. Reference: 4ab5f003-a3e3-43f4-a4db-99f3d9eb9fd1. Source status: eligible. Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement. Management context Stated as a priority in 2 of last 2 quarters. Net loss increased from approximately $1.0 million in 2026-Q1 to $5.8 million in 2026-Q2, while cash decreased from $11.2 million to $10.3 million, providing runway into Q3 2027. The trajectory shows ongoing operating losses with cash burn consistent with clinical development. Delivery assessment Oct 24, 2026
Positive clinical study results support product viability	Turn Therapeutics shows progress with a new drug study.	Intact	No positive clinical results published within next 4 quarters	Positive results published vs target: publish by next 4 quarters Turn Therapeutics published positive GX-03 dermatitis study results on 2026-05-27, meeting the clinical viability target. Context reviewed through Oct 23, 2026Last status assessment Oct 24, 2026Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement.

Stored thesis · Jul 8, 2026. Latest Evidence uses source-matched measurements where available, alongside the last thesis-monitor assessment. Source periods and assessment dates are shown separately. A new measurement does not automatically change the published status or verify an older target.

Incoming Evidence

Compare these dated observations with the operating requirements above

Expectations trend

Same fiscal period

FY2027 · fiscal year ending 2027-12-31 · fmp

FY2027 EPS: comparable history unavailable.

FY2027 revenue: comparable history unavailable.

Exact estimates & source dates

One fiscal period and provider throughout. At least five contributors are required for each plotted metric; missing coverage stays a gap. Axes show the observed range. Counts measure coverage, not revisions.

FY2027 estimate observations · fmp
Snapshot	EPS	Revenue	EPS / revenue analysts
2026-07-24	Unavailable	Unavailable	1 / 1
2026-07-25	Unavailable	Unavailable	1 / 1
2026-07-26	Unavailable	Unavailable	1 / 1
2026-07-27	Unavailable	Unavailable	1 / 1
2026-07-28	Unavailable	Unavailable	1 / 1
2026-07-29	Unavailable	Unavailable	1 / 1
2026-07-30	Unavailable	Unavailable	1 / 1
2026-07-31	Unavailable	Unavailable	1 / 1
2026-08-01	Unavailable	Unavailable	1 / 1
2026-08-02	Unavailable	Unavailable	1 / 1
2026-08-03	Unavailable	Unavailable	1 / 1
2026-08-04	Unavailable	Unavailable	1 / 1
2026-08-05	Unavailable	Unavailable	1 / 1
2026-08-06	Unavailable	Unavailable	1 / 1
2026-08-08	Unavailable	Unavailable	1 / 1
2026-08-09	Unavailable	Unavailable	1 / 1
2026-08-10	Unavailable	Unavailable	1 / 1
2026-08-12	Unavailable	Unavailable	1 / 1
2026-08-13	Unavailable	Unavailable	1 / 1
2026-08-14	Unavailable	Unavailable	1 / 1
2026-08-15	Unavailable	Unavailable	1 / 1
2026-08-16	Unavailable	Unavailable	1 / 1
2026-08-17	Unavailable	Unavailable	1 / 1
2026-08-18	Unavailable	Unavailable	1 / 1
2026-08-19	Unavailable	Unavailable	1 / 1
2026-08-20	Unavailable	Unavailable	1 / 1
2026-08-21	Unavailable	Unavailable	1 / 1
2026-08-22	Unavailable	Unavailable	1 / 1
2026-08-23	Unavailable	Unavailable	1 / 1
2026-08-24	Unavailable	Unavailable	1 / 1
2026-08-25	Unavailable	Unavailable	1 / 1
2026-08-26	Unavailable	Unavailable	1 / 1
2026-08-27	Unavailable	Unavailable	1 / 1
2026-08-28	Unavailable	Unavailable	1 / 1
2026-08-29	Unavailable	Unavailable	1 / 1
2026-08-30	Unavailable	Unavailable	1 / 1
2026-08-31	Unavailable	Unavailable	1 / 1
2026-09-01	Unavailable	Unavailable	1 / 1
2026-09-02	Unavailable	Unavailable	1 / 1
2026-09-03	Unavailable	Unavailable	1 / 1
2026-09-04	Unavailable	Unavailable	1 / 1
2026-09-05	Unavailable	Unavailable	1 / 1
2026-09-06	Unavailable	Unavailable	1 / 1
2026-09-07	Unavailable	Unavailable	1 / 1
2026-09-08	Unavailable	Unavailable	1 / 1
2026-09-09	Unavailable	Unavailable	1 / 1
2026-09-10	Unavailable	Unavailable	1 / 1
2026-09-11	Unavailable	Unavailable	1 / 1
2026-09-12	Unavailable	Unavailable	1 / 1
2026-09-13	Unavailable	Unavailable	1 / 1
2026-09-14	Unavailable	Unavailable	1 / 1
2026-09-15	Unavailable	Unavailable	1 / 1
2026-09-16	Unavailable	Unavailable	1 / 1
2026-09-17	Unavailable	Unavailable	1 / 1
2026-09-18	Unavailable	Unavailable	1 / 1
2026-09-19	Unavailable	Unavailable	1 / 1
2026-09-20	Unavailable	Unavailable	1 / 1
2026-09-21	Unavailable	Unavailable	1 / 1
2026-09-22	Unavailable	Unavailable	1 / 1
2026-09-23	Unavailable	Unavailable	1 / 1
2026-09-24	Unavailable	Unavailable	1 / 1
2026-09-25	Unavailable	Unavailable	1 / 2
2026-09-26	Unavailable	Unavailable	1 / 2
2026-09-27	Unavailable	Unavailable	1 / 2
2026-09-28	Unavailable	Unavailable	1 / 2
2026-09-29	Unavailable	Unavailable	1 / 2
2026-09-30	Unavailable	Unavailable	1 / 2
2026-10-01	Unavailable	Unavailable	1 / 2
2026-10-02	Unavailable	Unavailable	1 / 2
2026-10-03	Unavailable	Unavailable	1 / 2
2026-10-04	Unavailable	Unavailable	1 / 2
2026-10-05	Unavailable	Unavailable	1 / 2
2026-10-06	Unavailable	Unavailable	1 / 2
2026-10-07	Unavailable	Unavailable	1 / 2
2026-10-08	Unavailable	Unavailable	1 / 2
2026-10-09	Unavailable	Unavailable	1 / 2
2026-10-10	Unavailable	Unavailable	1 / 2
2026-10-11	Unavailable	Unavailable	1 / 2
2026-10-12	Unavailable	Unavailable	1 / 2
2026-10-13	Unavailable	Unavailable	1 / 2
2026-10-14	Unavailable	Unavailable	1 / 2
2026-10-15	Unavailable	Unavailable	1 / 2
2026-10-16	Unavailable	Unavailable	1 / 2
2026-10-17	Unavailable	Unavailable	1 / 2
2026-10-18	Unavailable	Unavailable	1 / 2
2026-10-19	Unavailable	Unavailable	1 / 2
2026-10-20	Unavailable	Unavailable	1 / 2
2026-10-21	Unavailable	Unavailable	1 / 2
2026-10-22	Unavailable	Unavailable	1 / 2
2026-10-23	Unavailable	Unavailable	1 / 2
2026-10-24	Unavailable	Unavailable	1 / 2

Revenue and EPS estimates track expectations. They are not delivered results or like-for-like proof of a required annual path.

Compare required revenue and earnings

Analyst view

Monthly observations

Buy / Strong BuyHoldSell / Strong Sell

Exact monthly counts

Monthly rating snapshots · fmp. Missing snapshots are not zero.
Date	Buy*	Hold	Sell*
2026-05-01	1	0	0
2026-06-01	1	0	0
2026-07-01	1	0	0
2026-08-01	1	0	0
2026-09-01	2	0	0
2026-10-01	2	0	0

*Buy includes Strong Buy; Sell includes Strong Sell. Monthly counts describe the analyst mix, not the firms behind each recent action.

Latest: 2 Buy / Strong Buy · 0 Hold · 0 Sell / Strong Sell

1 upgrades0 downgrades0 maintains

Recent actions · Sep 25–Oct 24 · 1 recorded

Price-target changes

30 days

Individual price-target observations are unavailable.

0 raises · 0 cuts · 0 unchanged · 0 without a comparable prior

How this is measured

Sep 25, 2026–Oct 24, 2026. Each firm's latest positive target is paired only with its immediately prior positive target from the same provider, at most 180 days earlier. Unmatched observations have one dot; conflicting observations are not compared.

Outlook in Brief

The evidence, the remaining questions, and what comes next

What's improving

No recovery evidence is reported in the available driver assessments.

Still unresolved / key risks

Expand board with independent directors for better governanceQualitative condition
Operating income loss stays near or below -$1.25 millionPublished status: Under Pressure

Next proof point

Nov 12, 2026

Look for updated results and guidance against the published targets, plus direct evidence for unresolved drivers.

Review earnings

Bottom line

2 of 4 published conditions remain under pressure or need verification. The next results need to address those conditions.

The dated weekly assessment and its assumptions are available in Read detailed Outlook.

Historical risk context

Observed price history; separate from operating scenarios

Price sensitivity

3.6%Typical daily move · historical

Downside history

-48.4%Maximum drawdown · trailing year

Read detailed Outlook Company context, assumptions & risks

Turn Therapeutics Inc outlook in detail

The weekly editorial context below is a separate assessment from the dated monitor evidence above. Recovery observations do not automatically change the published thesis. Unverified outside influences are hypotheses, not measured driver evidence.

Updated Oct 24, 2026

What kind of bet this is

This is a speculative clinical-stage biotech, not a proven durable compounder. The long-term thesis is intact, but confidence is low and the risk level is high.

What's priced into Turn Therapeutics Inc

The evidence does not provide a peer valuation comparison or a clear account of what expectations are reflected in the valuation. TTRX is loss-making, so the available evidence does not support a firm view on whether it is cheap, fair, or expensive.

What the fundamentals likely do

Near term, management says GX-03's Phase 2 atopic dermatitis trial is on track, with enrollment expanded to 120-135 patients and completion planned by the end of 2026. Cash of $10.3 million in 2026-Q2 was reported to provide runway into Q3 2027, but a recent earnings miss and equity financing activity add uncertainty.

What Turn Therapeutics Inc hinges on